Mukil Mohan has more than fifteen years of experience in systems engineering and management. With a background in both electrical engineering and management, he develops operational and business strategies to complement INanoBio’s technology and product development roadmaps. He has extensive experience leading high productivity cross functional teams. He has a Master’s degree in Electrical Engineering from the Ira A. Fulton School of Engineering and an MBA from the W.P. Carey School of Business both at Arizona State University in Tempe.
GENOME SEQUENCING
Sequencing a person’s genome can identify susceptibility to various diseases, aid in early disease diagnosis, and enable precision medicine – personalization of therapy based on individual specific genomic biomarkers.
CANCER DIAGNOSTICS
Detecting diseases in early stages dramatically improves therapeutic outcomes. In Cancer, average 5 year survival rate is close to 90% when diagnosed at stage 1, and stands at less than 25% when diagnosed at stage 4. In contrast, cost of therapy when diagnosed post metastasis is approximately 2.5 times that when diagnosed at early stages.
